HERVolution Data: HERV-K Expressed Across 43 Cancer Types
Image
COPENHAGEN – October 29, 2026 -- HERVolution Therapeutics ApS published peer-reviewed data in the Journal of Translational Medicine showing HERV-K expression across the majority of 43 cancer types in RNA sequencing data from 1,353 patients, backing the target rationale for its lead program, IPT-001.
HERV-K expression spans nearly all cancer types examined
The analysis used data from the Copenhagen Prospective Personalized Oncology study (CoPPO, NCT02290522), which enrolled patients with advanced, predominantly pre-treated cancer. Most patients showed more than 100 HML-2 reads per million total reads across the 43 cancer types, cancers of unknown primary and unclassified tumors. The authors say this extends earlier indication-specific reports.